Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GeparTrio study

Journal of the National Cancer Institute

Volumn 100, Issue 8, 2008, Pages 552-562

  Von Minckwitz, Gunter ^a,k   Kümmel, Sherko ^b   Vogel, Petra ^c   Hanusch, Claus ^d   Eidtmann, Holger ^e   Hilfrich, Jörn ^f   Gerber, Bernd ^g   Huober, Jens ^h   Costa, Serban Dan ⁱ   Jackisch, Christian ^j   Loibl, Sibylle ^a,k   Mehta, Keyur ^a   Kaufmann, Manfred ^k  

^a German Breast Group   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

^d Frauenklinik vom Roten Kreuz   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Henriettenstiftung   (Germany)

^g ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^j Klinikum Offenbach   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; TAC PROTOCOL; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CARDIOMYOPATHY; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EARLY CANCER; ECHOMAMMOGRAPHY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN; STOMATITIS; TACHYCARDIA; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; ECHOGRAPHY; GERMANY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RISK; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; ODDS RATIO; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RESEARCH DESIGN; TAXOIDS; TREATMENT OUTCOME; ULTRASONOGRAPHY, MAMMARY;

EID: 43149114454     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn089     Document Type: Article

References (24)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940-1949.
2. Muller C, Caputo A, Schumacher M, et al. Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial. Eur J Cancer. 2007;43(11):1654-1661.
3. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-2313.
4. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001;19(2):314-321.
5. von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005;16(1):56-63.
6. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or post-operative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2027.
7. Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2007;25(15):2012-2018.
8. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group [NCT00543829]. J Clin Oncol. 2005;23(12):2676-2685.
9. von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542-551.
10. Sinn HP, Schmid H, Junkermann H, et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy [in German]. Geburtshilfe Frauenheilkd. 1994;54(10):552-558.
11. von Minckwitz G, Sinn HP, Raab G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast [NCT00543829]. Breast Cancer Res. 2007 In press.
12. Fisher LD. Self-designing clinical trials. Stat Med. 1998;17(14):1551-1562.
13. von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim {+/-} ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2007;19(2):292-298.
14. TNM Classification of Malignant Tumours. 6th ed. Hoboken, NJ: John Wiley & Sons; 2002.
15. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11(3):359-377.
16. Diagnostic and treatment of patients with primary and metastatic breast cancer, complete guidelines of AGO Breast Commission 2008. http://www.ago- online.org/index.php?lang=de& site=mamma_guide_08_1_0&topic=mamma_guide. Accessed March 13, 2008.
17. Mazouni C, Kau SW, Frye D, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007;18(5):874-880.
18. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17(8):1228-1233.
19. Loibl S, Blohmer JU, Raab G, Steffen J, Kaufmann M, Lohr A. Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline/taxane based regimen in the multicenter GparTrio trial [abstract]. Breast Cancer Res Treat. 2005;94(suppl 1):Abstract 1023.
20. Loibl S, von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13(11):1434-1442.
21. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17(8):2341-2354.
22. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21(6):968-975.
23. Ewer MS, Benjamin RS. Toxicities of chemotherapeutic drugs. In: Perry MC, editors. The Chemotherapy Source Book. 3rd ed. Baltimore, MD: Lippincott Williams & Wilkens; 2001:458-468.
24. von Minckwitz G, Rezai M, Loibl S, et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study GeparQuattro. San Antonio Breast Cancer Symposium; San Antonio, TX: 2007; Abstract 79.